| Literature DB >> 34926838 |
Briana Simpson1, Mark M Rich2, Andrew A Voss3, Robert J Talmadge1.
Abstract
Huntington's disease (HD) causes neurological impairments, as well as muscle dysfunction, including smaller neuromuscular junctions (NMJs). This study assessed the expression levels of the subunits of the nicotinic acetylcholine receptor (nAChR) in muscles of the R6/2 mouse model of HD. Based on our previous findings of reduced NMJ size in R6/2 mice, it was hypothesized that muscles from R6/2 mice would also show an altered expression pattern of nAChR subunits compared to wild-type (WT) mice. Therefore, the mRNA levels of nAChR subunits were quantified in R6/2 and WT mouse muscles using qRT-PCR. Denervated muscles from WT mice served as positive controls for alterations in nAChR expression. Although some changes in nAChR subunit expression occurred in R6/2 muscles, the expression levels closely resembled WT. However, the expression of nAChR subunit-ε (Chrne) was significantly decreased in R6/2 muscles relative to WT. This study demonstrates that only minor changes in nAChR subunit expression occurs in R6/2 mouse muscles and that reduction in Chrne expression may be related to a reduction in NMJ size in R6/mice.Entities:
Keywords: Acetylcholine receptor; Denervation; Huntington's disease; R6/2; Skeletal muscle
Year: 2021 PMID: 34926838 PMCID: PMC8649948 DOI: 10.1016/j.bbrep.2021.101182
Source DB: PubMed Journal: Biochem Biophys Rep ISSN: 2405-5808
Reverse transcriptase polymerase chain reaction gene expression assays.
| Common Name | Gene nomenclature | TaqMan® Expression Assay |
|---|---|---|
| nAChR, α subunit | Mm00431629_m1 | |
| nAChR, β subunit | Mm00680412_m1 | |
| nAChR, δ subunit | Mm00445545_m1 | |
| nAChR, ε subunit | Mm00437411_m1 | |
| nAChR, γ subunit | Mm00437419_m1 | |
| Voltage-gated Na+ channel, cardiac isoform | Mm01342518_m1 | |
| β-2-microglobulin | Mm00437762_m1 |
All TaqMan® Expression Assays were obtained from Applied Biosystems™, Foster City, CA. Abbreviations: nAChR, nicotinic acetylcholine receptor.
Fig. 2Relative expression levels as determined by real-time RT-PCR for the subunits of the nicotinic acetylcholine receptor: Chrna1 (alpha); Chrnb1 (beta); Chrng (gamma); Chrnd (delta); and Chrne (epsilon) in A) Denervated gastrocenemius muscle (n = 7 per group) relative to control; B) gastrocnemius muscle (n = 6 per group) from late-stage R6/2 and WT mice; C) EDL muscle (n = 6 per group) from late-stage R6/2 and WT mice; and D) soleus muscle (n = 11 WT and 10 R6/2) from late-stage R6/2 and WT mice. Denervation (A) resulted in major elevations in the expression levels of all subunits except Chrne which was reduced. In contrast R6/2 mice show no (or minor) changes in nicotinic acetylcholine receptor subunits, except for a consistent decrease in Chrne. The asterisks denote significantly different from control at p < 0.05.
Fig. 1A) Gastrocnemius (Gastroc) muscle masses from control (n = 7) and denervated (n = 7) mice. Denervation resulted in a near 50% loss in muscle mass. B) Gastroc (n = 6 per group), extensor digitorum longus (EDL, n = 6 per group), and soleus (n = 11 WT and 10 R6/2) muscle masses from late-stage R6/2 and wild type (WT) mice. Muscles in R6/2 mice show significant reductions in muscle mass. The asterisks denote significantly different from control at p < 0.05.
Fig. 3A. Relative expression levels as determined by real-time RT-PCR for the cardiac isoform of the sodium channel (Scn5a) in Denervated gastrocenemius (Gastroc Den.) muscle (n = 7 per group) relative to control; and gastrocnemius (Gast) muscle (n = 6 per group) from late-stage R6/2 and WT mice; EDL muscle (n = 6 per group) from late-stage R6/2 and WT mice; and soleus (Sol) muscle (n = 11 WT and 10 R6/2) from late-stage R6/2 and WT mice. The asterisks denote significantly different from control at p < 0.05. B. Relative expression levels as determined by real-time RT-PCR for Chrng in the tibialis anterior muscle at 3 disease stages (ages) according to Miranda et al. [16] as follows: Early-stage, ages 23–46 days of age (n = 10 per group); Mid-stage, ages 47–69 days of age (n = 9 WT and 10 R6/2); and Late-stage, ages 70–92 days of age (n = 6 per group). No significant differences were observed between R6/2 and WT at any time point.